60. Aplastic anemia Clinical trials / Disease details
Clinical trials : 235 / Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01267643 (ClinicalTrials.gov) | May 2011 | 20/12/2010 | Alefacept in Patients With Relapsed/Refractory Aplastic Anemia | A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia | Aplastic Anemia | Drug: Alefacept | The Cleveland Clinic | Astellas Pharma US, Inc. | Terminated | 18 Years | N/A | All | 4 | Phase 1 | United States |
| 2 | NCT01319851 (ClinicalTrials.gov) | September 2010 | 15/9/2010 | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study | Thalassemia;Sickle Cell Disease;Glanzmann Thrombasthenia;Wiskott-Aldrich Syndrome;Chronic-granulomatous Disease;Severe Congenital Neutropenia;Leukocyte Adhesion Deficiency;Schwachman-Diamond Syndrome;Diamond-Blackfan Anemia;Fanconi Anemia;Dyskeratosis-congenita;Chediak-Higashi Syndrome;Severe Aplastic Anemia | Drug: Alefacept | Emory University | Children's Healthcare of Atlanta | Terminated | N/A | 21 Years | All | 3 | N/A | United States |